Unisensor has developed a unique sensor technology which enables analysis of the bacteria levels in fluids, including blood, urine, water and milk. Further, Unisensor’s scanning device is capable of following the development of cancer cells, which enables the monitoring of the effect of chemotherapy on cancer patients. ATRIUM has acted as advisor to the shareholders of Unisensor A/S in connection with the sale of the company to Philips. With the acquisition, Philips will strengthen its activities and product portfolio within remote patient monitoring, but will also allow Philips to develop devices for liquid analysis in other areas. Unisensor will become part of the Philips Healthcare division. In the sales process, ATRIUM drew on its international network in the MidCap Alliance to include a number of interested parties around the world.